Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (ipf) by stimulating the growth of stem cells directly in the lungs, a study reports. Bexotegrast, an investigational oral treatment for ipf from pliant therapeutics, is now moving into a pivotal, adaptive phase 2b/3 trial. Inhibiting the hif2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for treating ipf. Cs014, a treatment candidate for idiopathic pulmonary fibrosis (ipf), was found to be safe and well tolerated in healthy volunteers in a phase 1 clinical trial, according to new data from developer cereno scientific. Zelasudil, an experimental treatment seen to lessen scarring in idiopathic pulmonary fibrosis (ipf), is granted fda orphan drug status. Pulmonary fibrosis news forums welcome lounge this forum is welcome to all members of the pf/ipf community
Topics will primarily be applicable to patients, however,…
WATCH
